Advancing MedTech Integration and Driving Surgical Innovation
On August 12, 2025, Shenzhen SurgSci Medical Technology Co., Ltd. (“SurgSci”) and Jinhua Central Hospital of Zhejiang Province held a strategic cooperation signing ceremony and academic exchange meeting. Representatives from both parties engaged in in-depth discussions on aligning minimally invasive surgical innovation with clinical needs and formally established a collaborative partnership.
Clinical Alignment and Strategic Dialogue
The meeting was chaired by Mr. Xue Yadong, Director of Scientific Research at Jinhua Central Hospital. Mr. Yu Shian, Deputy Party Secretary and President of the hospital, delivered the opening address.
President Yu emphasized the increasing demand for diversity and precision in surgical instruments, particularly in foundational tools for advanced tissue dissection and hemostasis. Variations in length, diameter, and articulation angles can significantly affect surgical outcomes. This complexity presents broad opportunities for joint innovation between hospitals and enterprises. He commended SurgSci’s technical capabilities and collaborative sincerity, expressing hope for deeper cooperation that leverages the strengths of both sides.
Mr. Lü Dawei, Chairman of SurgSci, introduced the company’s development trajectory and strategic positioning. Founded in 2017, SurgSci is an innovation-driven enterprise specializing in the research, development, and manufacturing of minimally invasive surgical instruments. The company has achieved multiple technological breakthroughs in titanium alloys, piezoelectric ceramics, polymer materials, and artificial intelligence algorithms. Its proprietary multi-degree-of-freedom ultrasonic scalpel is globally leading and has entered clinical validation. As part of a 2022 National Key R&D Program, SurgSci has realized full-chain, system-level innovation from materials to devices, systems, and clinical applications. Mr. Lü noted that while the technology has made significant progress, targeted optimization based on clinical feedback remains essential. He expressed strong interest in collaborating with Jinhua Central Hospital to jointly advance the development of innovative medical devices.
Signing Ceremony and Department Overview
Under the witness of attendees, both parties formally signed the cooperation agreement.
Following the signing, Dr. Yu Min, Director of the Hepatobiliary and Pancreatic Surgery Department at Jinhua Central Hospital, provided an overview of the department. As a National Clinical Key Specialty, the department—under the leadership of President Yu—has demonstrated notable strengths in minimally invasive hepatobiliary procedures, performing numerous complex surgeries with a high proportion of minimally invasive techniques, some of which are firsts in China.
Current research focuses include multimodal real-time navigation for liver cancer surgery, intraoperative ultrasound monitoring patch systems, and novel ultrasonic energy devices—all of which are closely aligned with SurgSci’s technical domains.
Mr. Feng Gengchao, Founder of SurgSci, elaborated on the company’s product philosophy: “Technological innovation to empower physicians and benefit patients.” Over the past eight years, SurgSci has focused on three core areas—metal materials, polymer materials, and artificial intelligence algorithms—building a dual-engine product ecosystem of “devices + materials.” Breakthroughs include globally leading ultrasonic scalpel material solutions, articulating ultrasonic scalpel technology, and the world’s first pediatric-specific ultrasonic scalpel. Mr. Feng emphasized that only through a deep understanding of clinical needs can truly effective products be developed, and expressed eagerness for substantive collaboration with Jinhua Central Hospital.
Targeted Innovation and Accelerated Translation
During the roundtable discussion, both parties explored technical challenges in liver surgery, focusing on the clinical adaptability and operational feasibility of new ultrasonic surgical instruments in complex procedures such as diaphragmatic dome dissection. President Yu proposed leveraging the hospital’s existing animal testing platform to accelerate product validation and define priority collaboration areas. Through surgical observation and hands-on training, key operational steps and clinical requirements will be systematically mapped to support future research and development.
The teams also exchanged views on critical performance metrics such as ultrasonic energy control and cutting efficiency, reaching preliminary consensus on strengthening clinical-R&D integration. Preparations for joint scientific platform applications were advanced, with clear plans for material supplementation, collaboration mechanisms, and follow-up pathways. Both parties committed to maintaining efficient communication and fast-tracking key initiatives to achieve tangible progress in technology translation and research synergy.
Conclusion
This meeting marks the formal establishment of a strategic partnership between SurgSci and Jinhua Central Hospital. The collaboration will integrate the hospital’s deep clinical expertise and advanced treatment concepts with SurgSci’s strengths in precision instrument design, materials innovation, and system development. Together, the two parties will address clinical pain points through coordinated innovation. Looking ahead, the partnership will continue to expand in scope, jointly promoting the high-quality development of domestic medical devices and delivering solutions that better meet real-world clinical needs.
About Jinhua Central Hospital
Founded in 1910, Jinhua Central Hospital is a top-tier tertiary general hospital in central-western Zhejiang Province, integrating medical care, research, education, prevention, wellness, and rehabilitation. In 2020, it was designated as an affiliated hospital of Zhejiang University School of Medicine. For six consecutive years, it has ranked in the A+ tier of China’s national performance evaluation for tertiary public hospitals, consistently among the country’s top 100.
The hospital spans 93.98 acres, with over 230,000 square meters of medical facilities, 2,578 open beds, and a workforce of 4,028. It boasts 732 senior professionals and 930 master’s and doctoral degree holders, including national stipend experts and provincial-level talent.
It currently hosts two national key clinical specialties, seven provincial key specialties, nine provincial regional disease centers, and multiple co-built disciplines, covering high-incidence and high-difficulty fields such as neurosurgery, general surgery, gastroenterology, and cardiothoracic surgery. Equipped with cutting-edge technologies such as the fourth-generation Da Vinci surgical robot, hybrid operating rooms, and 3D laparoscopes, the hospital has significantly enhanced its capabilities in minimally invasive and complex procedures. As a national advanced stroke center, chest pain center, and trauma center, it continues to grow in surgical volume and technical excellence, providing robust support for the diagnosis and treatment of critical and complex conditions in the region.
